NCT05884320 2026-03-11Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersM.D. Anderson Cancer CenterPhase 2 Recruiting30 enrolled
NCT00939627 2026-03-10Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabNational Cancer Institute (NCI)Phase 2 Completed55 enrolled 10 charts
NCT06695845 2026-02-25A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsJazz PharmaceuticalsPhase 2 Recruiting200 enrolled
NCT04620187 2026-02-24Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasDana-Farber Cancer InstitutePhase 2 Recruiting55 enrolled